Do analysts prefer ANEB or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 918.81%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ANEB or MREO more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts recommend INKT or ANEB?

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 211.25%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, INKT or ANEB?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is INKT or ANEB more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Does the media prefer INKT or ANEB?

In the previous week, MiNK Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for MiNK Therapeutics and 1 mentions for Anebulo Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 1.31 beat Anebulo Pharmaceuticals' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anebulo Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INCR or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is INCR or ANEB more profitable?

InterCure's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts recommend TIL or ANEB?

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 759.38%. Given Instil Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, TIL or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is TIL or ANEB more profitable?

Instil Bio's return on equity of -39.76% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate ANEB or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ANEB or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% ABVC BioPharma N/A -62.46% -39.99%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.34 0.00 (0.00%)

As of 09:32 AM Eastern

Compare

ANEB vs. MREO, INKT, INCR, TIL, and ABVC

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? MarketBeat compares Anebulo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anebulo Pharmaceuticals include Mereo BioPharma Group (MREO), MiNK Therapeutics (INKT), InterCure (INCR), Instil Bio (TIL), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry.

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Anebulo Pharmaceuticals has a beta of -1.83, indicating that its share price is 283% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

In the previous week, Anebulo Pharmaceuticals and Anebulo Pharmaceuticals both had 1 articles in the media. Mereo BioPharma Group's average media sentiment score of 1.87 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 918.81%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Mereo BioPharma Group	$500K	101.84	-$41.88M	-$0.05	N/A

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Mereo BioPharma Group beats Anebulo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, indicating that its stock price is 283% less volatile than the broader market.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 211.25%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

MiNK Therapeutics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

In the previous week, MiNK Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for MiNK Therapeutics and 1 mentions for Anebulo Pharmaceuticals. MiNK Therapeutics' average media sentiment score of 1.31 beat Anebulo Pharmaceuticals' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anebulo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

MiNK Therapeutics beats Anebulo Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to InterCure?

InterCure (NASDAQ:INCR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

InterCure has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, meaning that its stock price is 283% less volatile than the broader market.

8.3% of InterCure shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Anebulo Pharmaceuticals has lower revenue, but higher earnings than InterCure. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.68	-$10.37M	$0.03	32.57
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, InterCure had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for InterCure and 1 mentions for Anebulo Pharmaceuticals. InterCure's average media sentiment score of 1.45 beat Anebulo Pharmaceuticals' score of 0.00 indicating that InterCure is being referred to more favorably in the media.

Company	Overall Sentiment
InterCure	Positive
Anebulo Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

InterCure's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Summary

InterCure beats Anebulo Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Instil Bio has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, indicating that its stock price is 283% less volatile than the broader market.

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 759.38%. Given Instil Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.87 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Anebulo Pharmaceuticals	Neutral

Instil Bio's return on equity of -39.76% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Summary

Instil Bio beats Anebulo Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to ABVC BioPharma?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

ABVC BioPharma has higher revenue and earnings than Anebulo Pharmaceuticals. ABVC BioPharma is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
ABVC BioPharma	$510K	67.29	-$7.91M	-$0.40	N/A

ABVC BioPharma's return on equity of -62.46% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
ABVC BioPharma	N/A	-62.46%	-39.99%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anebulo Pharmaceuticals has a beta of -1.83, indicating that its stock price is 283% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

In the previous week, Anebulo Pharmaceuticals and Anebulo Pharmaceuticals both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 1.89 beat Anebulo Pharmaceuticals' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
ABVC BioPharma	Very Positive

Summary

ABVC BioPharma beats Anebulo Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.72M	$3.66B	$6.79B	$12.62B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-1.77	21.27	27.04	24.39
Price / Sales	N/A	314.78	521.74	91.34
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	1.20	8.51	10.83	6.31
Net Income	-$8.48M	$23.83M	$3.59B	$331.45M
7 Day Performance	N/A	-2.88%	-1.30%	0.26%
1 Month Performance	-29.56%	5.76%	2.97%	-0.64%
1 Year Performance	-78.57%	51.80%	28.58%	20.24%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	0.0381 of 5 stars	$0.34 flat	N/A	-79.1%	$13.72M	N/A	N/A	4
MREO Mereo BioPharma Group	3.2021 of 5 stars	$0.32 -5.5%	$3.25 +928.5%	-81.7%	$53.39M	$500K	N/A	40	Positive News
INKT MiNK Therapeutics	2.7679 of 5 stars	$10.55 -0.7%	$35.00 +231.8%	-71.9%	$52.91M	N/A	N/A	30	Positive News
INCR InterCure	1.3544 of 5 stars	$0.97 +0.5%	N/A	-36.1%	$52.76M	$78.47M	32.33	350	Positive News Short Interest Decrease Gap Down
TIL Instil Bio	1.6982 of 5 stars	$7.78 +0.4%	$66.00 +748.3%	-68.1%	$52.56M	N/A	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. MREO, INKT, INCR, TIL, and ABVC

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Summary

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to InterCure?

Summary

How does Anebulo Pharmaceuticals compare to Instil Bio?

Summary

How does Anebulo Pharmaceuticals compare to ABVC BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. MREO, INKT, INCR, TIL, and ABVC

How does Anebulo Pharmaceuticals compare to Mereo BioPharma Group?

Which has more risk and volatility, ANEB or MREO?

Is ANEB or MREO more profitable?

Does the media refer more to ANEB or MREO?

Do analysts prefer ANEB or MREO?

Which has stronger earnings and valuation, ANEB or MREO?

Do insiders and institutionals believe in ANEB or MREO?

Summary

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

Which has more risk & volatility, INKT or ANEB?

Do analysts recommend INKT or ANEB?

Is INKT or ANEB more profitable?

Does the media prefer INKT or ANEB?

Do insiders and institutionals hold more shares of INKT or ANEB?

Which has preferable valuation & earnings, INKT or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to InterCure?

Which has more risk & volatility, INCR or ANEB?

Do insiders & institutionals have more ownership in INCR or ANEB?

Which has higher valuation and earnings, INCR or ANEB?

Does the media favor INCR or ANEB?

Do analysts rate INCR or ANEB?

Is INCR or ANEB more profitable?

Summary

How does Anebulo Pharmaceuticals compare to Instil Bio?

Which has preferable valuation & earnings, TIL or ANEB?

Which has more risk & volatility, TIL or ANEB?

Do analysts recommend TIL or ANEB?

Do institutionals & insiders hold more shares of TIL or ANEB?

Does the media favor TIL or ANEB?

Is TIL or ANEB more profitable?

Summary

How does Anebulo Pharmaceuticals compare to ABVC BioPharma?

Which has better valuation and earnings, ANEB or ABVC?

Is ANEB or ABVC more profitable?

Do analysts rate ANEB or ABVC?

Do institutionals and insiders have more ownership in ANEB or ABVC?

Which has more risk & volatility, ANEB or ABVC?

Does the media refer more to ANEB or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools